SSA
PMCB icon

Schonfeld Strategic Advisors’s PharmaCyte Biotech PMCB Stock Holding History

Schonfeld Strategic Advisors’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18K Buy
27,009
+831
+3% +$636 ﹤0.01% 2062
2025
Q4 		$19K Sell
26,178
-22
-0.1% -$20 ﹤0.01% 1934
2025
Q3 		$25.4K Hold
26,200
– – ﹤0.01% 2097
2025
Q2 		$28.6K Buy
26,200
+700
+3% +$781 ﹤0.01% 1915
2025
Q1 		$31.9K Sell
25,500
-200
-0.8% -$325 ﹤0.01% 2084
2024
Q4 		$40.3K Sell
25,700
-200
-0.8% -$345 ﹤0.01% 1882
2024
Q3 		$49.5K Buy
25,900
+2,200
+9% +$4.1K ﹤0.01% 1888
2024
Q2 		$46.5K Buy
23,700
+200
+0.9% +$431 ﹤0.01% 1940
2024
Q1 		$55.7K Buy
23,500
+300
+1% +$649 ﹤0.01% 1895
2023
Q4 		$50.1K Sell
23,200
-100
-0.4% -$217 ﹤0.01% 1669
2023
Q3 		$48.9K Sell
23,300
-200
-0.9% -$510 ﹤0.01% 1538
2023
Q2 		$67.2K Sell
23,500
-500
-2% -$1.5K ﹤0.01% 1784
2023
Q1 		$69.8K Sell
24,000
-1,200
-5% -$3.53K ﹤0.01% 1741
2022
Q4 		$73.8K Buy
25,200
+400
+2% +$1.15K ﹤0.01% 2228
2022
Q3 		$60K Sell
24,800
-1,400
-5% -$3.54K ﹤0.01% 2618
2022
Q2 		$59K Sell
26,200
-100
-0.4% -$219 ﹤0.01% 2205
2022
Q1 		$60K Sell
26,300
-4,100
-13% -$9.11K ﹤0.01% 2316
2021
Q4 		$76K Sell
30,400
-57,800
-66% -$159K ﹤0.01% 1915
2021
Q3 		$280K Buy
+88,200
New +$310K ﹤0.01% 1569

Other funds holding PMCB

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Schonfeld Strategic Advisors's PMCB Position: Q1 2026 in Review

Schonfeld Strategic Advisors increased its PharmaCyte Biotech (PMCB) stake by 3.2% in Q1 2026, buying an estimated $636 and bringing the position to 27,009 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #2062.

Schonfeld Strategic Advisors first reported a position in PMCB in Q3 2021 and has held it in 19 quarters since. The position peaked at $280K in Q3 2021. 32 funds tracked by Wall St. Rank hold PMCB as of Q1 2026.

  • Schonfeld Strategic Advisors held 27,009 shares of PharmaCyte Biotech worth $18K as of Q1 2026.
  • Schonfeld Strategic Advisors bought 831 PharmaCyte Biotech shares in Q1 2026, an estimated $636.
  • PharmaCyte Biotech made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #2062 holding.
  • Schonfeld Strategic Advisors first reported a position in PharmaCyte Biotech in Q3 2021 and has held it in 19 quarters since.
  • Schonfeld Strategic Advisors's PharmaCyte Biotech position peaked at $280K in Q3 2021.
  • 32 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.